Study tracks development, integration of MTM
WASHINGTON — The concept of medication therapy management has become more developed, and certain aspects of it have become established within the organizations providing and paying for it, according to a white paper published in the Journal of the American Pharmacists Association.
Researchers from pharmacy schools at the University of Minnesota, the University of Iowa, the University of Southern California and the University of Oklahoma collected data for "environmental scans" from MTM providers and payers throughout the United States using self-administered online surveys conducted between 2007 and 2010.
The study found a need to integrate MTM between organizations and patients serviced, between partnering organizations and between collaborating healthcare providers and that "a ‘channel of distribution’ is emerging in which organizational relationships and cost efficiencies will be important considerations in the near term." The researchers suggested that customer portfolio management and transaction cost economics would help to integrate MTM into the U.S. healthcare system.
Click here to see the white paper.
Hi-Tech Pharmacal reports Q2
AMITYVILLE, N.Y. — Net sales for Hi-Tech Pharmacal rose 27% for its second quarter ended Oct. 31, the drug maker said.
Net sales for the three months were nearly $56.9 million, compared with about $44.7 million in the year-ago period. For its generic drug sales, Hi-Tech reported an increase of 33%, compared with second quarter 2012, which primarily was due to stronger sales of fluticasone propionate nasal spray. The company noted it also benefited from sales of gabapentin oral solution, ranitidine oral solution and lidocaine sterile jelly, all of which were launched this year, along with the company’s clobetasol line of topical products and buprenorphine.
Meanwhile, the company said its branded division, ECR Pharmaceuticals, contributed $3.5 million to sales in the current period, a decrease of $1.2 million, or 26%, compared with the year-ago period, mainly due to the discontinuation of the extended release versions in the Lodrane line of antihistamines. Increased sales of recently acquired products, including Tussicaps, partially offset the decrease in sales for the quarter, Hi-Tech Pharmacal said.
Walgreens pharmacy comps up 1.2%; Express Scripts, slow flu season are headwinds
DEERFIELD, Ill. — Walgreens on Monday reported November sales of $6.1 billion, an increase of 4.2%, compared with the same month in fiscal year 2011. Sales in comparable stores increased 1.8%.
Total front-end sales increased 4%, with comparable store front-end sales up 2.7%. Customer traffic in comparable stores decreased 30 basis points and basket size was up 3%.
November pharmacy sales increased 3.4%, while comparable pharmacy sales increased 1.2%. Prescriptions filled at comparable stores increased 60 basis points in November. Calendar day shifts in November, which had one additional Wednesday and one fewer Monday compared with November 2010, negatively impacted prescriptions filled in comparable stores by 40 basis points. Lower incidence of flu negatively impacted comparable prescriptions filled by 80 basis points.
The estimated negative impact on comparable prescriptions filled from prescription transfers and other trend analysis of prescriptions managed by Express Scripts was approximately 110 basis points. Despite this impact, total prescriptions filled grew by 150 basis points through the month, Walgreens reported.
Comparable pharmacy sales also were negatively impacted by 220 basis points due to generic drug introductions in the last 12 months and by 130 basis points due to lower incidence of cough, cold and flu. Pharmacy sales accounted for 64.7% of total sales for the month.
Flu shots administered at pharmacies and clinics season-to-date were 5 million, versus 5.4 million last year.